Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Iovance Biotherapeutics (IOVA) EBT: 2009-2024

Historic EBT for Iovance Biotherapeutics (IOVA) over the last 13 years, with Dec 2024 value amounting to -$375.0 million.

  • Iovance Biotherapeutics' EBT fell 10.11% to -$93.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$398.3 million, marking a year-over-year increase of 4.28%. This contributed to the annual value of -$375.0 million for FY2024, which is 16.20% up from last year.
  • Per Iovance Biotherapeutics' latest filing, its EBT stood at -$375.0 million for FY2024, which was up 16.20% from -$447.5 million recorded in FY2023.
  • In the past 5 years, Iovance Biotherapeutics' EBT ranged from a high of -$342.3 million in FY2021 and a low of -$447.5 million during FY2023.
  • For the 3-year period, Iovance Biotherapeutics' EBT averaged around -$406.1 million, with its median value being -$395.9 million (2022).
  • As far as peak fluctuations go, Iovance Biotherapeutics' EBT declined by 15.67% in 2022, and later rose by 16.20% in 2024.
  • Yearly analysis of 4 years shows Iovance Biotherapeutics' EBT stood at -$342.3 million in 2021, then declined by 15.67% to -$395.9 million in 2022, then fell by 13.04% to -$447.5 million in 2023, then increased by 16.20% to -$375.0 million in 2024.